Efficacy trial of heat-inactivated hepatitis B vaccine (CLB) in male homosexuals in the Netherlands

R. A. Coutinho; P. N. Lelie; P. Albrecht-van Lent; L. Stoutjesdijk; J. Huisman; H. Kuipers; L. J. Schut; E. E. Reerink-Brongers; H. W. Reesink; W. G. van Aken

Efficacy trial of heat-inactivated hepatitis B vaccine (CLB) in male homosexuals in the Netherlands

R. A. Coutinho
, P. N. Lelie
, P. Albrecht-van Lent
, L. Stoutjesdijk
, J. Huisman
, H. Kuipers
, L. J. Schut
, E. E. Reerink-Brongers
, H. W. Reesink
, W. G. van Aken

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

The efficacy of a heat-inactivated hepatitis B virus (HBV) vaccine, containing 3 micrograms-HBsAg, was studied among a group of 800 susceptible homosexual men. The trial was conducted randomized, placebo-controlled and double blind. At the trial end point (21.5 months) the attack-rate for all HBV infections together was 4.8% among vaccinees and 23.8% among the placebos (p less than 0.0001). Four months after the first injection 89% of the vaccinees had formed anti-HBs and this percentage declined only slightly during the follow-up period. Maximum titers were reached 5 months after the first vaccination. None of the vaccinees who responded to the vaccine with anti-HBs greater than or equal to 1 mIU/ml developed a HBsAg positive infection. The vaccine had no serious side-effects

Original language	English
Pages (from-to)	287-292
Journal	Developments in biological standardization
Volume	54
Publication status	Published - 1983

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

@article{b0fa43e4a4c945aa8f49f4a962b9c166,

title = "Efficacy trial of heat-inactivated hepatitis B vaccine (CLB) in male homosexuals in the Netherlands",

abstract = "The efficacy of a heat-inactivated hepatitis B virus (HBV) vaccine, containing 3 micrograms-HBsAg, was studied among a group of 800 susceptible homosexual men. The trial was conducted randomized, placebo-controlled and double blind. At the trial end point (21.5 months) the attack-rate for all HBV infections together was 4.8\% among vaccinees and 23.8\% among the placebos (p less than 0.0001). Four months after the first injection 89\% of the vaccinees had formed anti-HBs and this percentage declined only slightly during the follow-up period. Maximum titers were reached 5 months after the first vaccination. None of the vaccinees who responded to the vaccine with anti-HBs greater than or equal to 1 mIU/ml developed a HBsAg positive infection. The vaccine had no serious side-effects",

author = "Coutinho, \{R. A.\} and Lelie, \{P. N.\} and \{Albrecht-van Lent\}, P. and L. Stoutjesdijk and J. Huisman and H. Kuipers and Schut, \{L. J.\} and Reerink-Brongers, \{E. E.\} and Reesink, \{H. W.\} and \{van Aken\}, \{W. G.\}",

year = "1983",

language = "English",

volume = "54",

pages = "287--292",

journal = "Developments in biological standardization",

issn = "0301-5149",

publisher = "S. Karger AG",

}

TY - JOUR

T1 - Efficacy trial of heat-inactivated hepatitis B vaccine (CLB) in male homosexuals in the Netherlands

AU - Coutinho, R. A.

AU - Lelie, P. N.

AU - Albrecht-van Lent, P.

AU - Stoutjesdijk, L.

AU - Huisman, J.

AU - Kuipers, H.

AU - Schut, L. J.

AU - Reerink-Brongers, E. E.

AU - Reesink, H. W.

AU - van Aken, W. G.

PY - 1983

Y1 - 1983

N2 - The efficacy of a heat-inactivated hepatitis B virus (HBV) vaccine, containing 3 micrograms-HBsAg, was studied among a group of 800 susceptible homosexual men. The trial was conducted randomized, placebo-controlled and double blind. At the trial end point (21.5 months) the attack-rate for all HBV infections together was 4.8% among vaccinees and 23.8% among the placebos (p less than 0.0001). Four months after the first injection 89% of the vaccinees had formed anti-HBs and this percentage declined only slightly during the follow-up period. Maximum titers were reached 5 months after the first vaccination. None of the vaccinees who responded to the vaccine with anti-HBs greater than or equal to 1 mIU/ml developed a HBsAg positive infection. The vaccine had no serious side-effects

AB - The efficacy of a heat-inactivated hepatitis B virus (HBV) vaccine, containing 3 micrograms-HBsAg, was studied among a group of 800 susceptible homosexual men. The trial was conducted randomized, placebo-controlled and double blind. At the trial end point (21.5 months) the attack-rate for all HBV infections together was 4.8% among vaccinees and 23.8% among the placebos (p less than 0.0001). Four months after the first injection 89% of the vaccinees had formed anti-HBs and this percentage declined only slightly during the follow-up period. Maximum titers were reached 5 months after the first vaccination. None of the vaccinees who responded to the vaccine with anti-HBs greater than or equal to 1 mIU/ml developed a HBsAg positive infection. The vaccine had no serious side-effects

M3 - Article

C2 - 6228469

SN - 0301-5149

VL - 54

SP - 287

EP - 292

JO - Developments in biological standardization

JF - Developments in biological standardization

ER -

Efficacy trial of heat-inactivated hepatitis B vaccine (CLB) in male homosexuals in the Netherlands

Abstract

UN SDGs

Fingerprint

Cite this